Oncology Pilot To Highlight Disagreements Between US FDA And Sponsor For Advisory Committees
Executive Summary
'Point/Counterpoint' program grew out of Assessment Aid initiative in the Oncology Center of Excellence and will be unveiled at an upcoming ODAC meeting.
You may also be interested in...
Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC
OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.
Point-Counterpoint: US FDA Adcomm Joint Briefing Document Likely Limited To Oncology For Now
Oncology Center of Excellence Director Richard Pazdur wants to make the single, joint backgrounder standard for Oncologic Drugs Advisory Committee meetings; former Peripheral and Central Nervous System Drugs adcomm member Caleb Alexander says the joint document is risky, citing the negative experience with Biogen's Aduhelm.
US FDA’s Oncology Center In The Lockdown: ‘Business As Usual’
Amid the COVID-19 pandemic, Richard Pazdur doesn’t want the cancer patient forgotten. His solution: keep churning out approvals.